India Pharma Outlook Team | Thursday, 15 October 2026
India’s centre drives a decisive pharma push that strengthens patient safety, expands clinical research infrastructure, and improves emergency care.
Recent moves include a high-level review of coronary stent safety, a strategic partnership to upgrade 25 clinical trial sites under the Biopharma SHAKTI policy, and coordinated state-level action that builds emergency care capacity on major highways.
These steps signal active government involvement that prioritizes quality, innovation, and timely treatment.
Policymakers focus on rigorous regulation, wider research networks beyond metros, and faster trauma response during the critical golden hour.
Together, the initiatives create a coherent narrative of intervention that elevates healthcare standards and positions India as a stronger player in global pharmaceutical research and patient protection.
The Cabinet Secretariat directs the Union Health Ministry to examine safety and quality concerns surrounding certain India-made drug-eluting coronary stents. Rajya Sabha member and medical doctor Ajeet Madhavrao Gopchade flags the issues in a representation to the Cabinet Secretariat.
He highlights three stent models that Sri Lanka’s medical device regulator directed for withdrawal after an investigation by the medical device evaluation committee. Reports cite problems such as improper positioning, stent dislodgement, acute stent thrombosis, and failure to expand properly.
Gopchade stresses that India must examine these patient safety issues carefully and address them proactively. He urges the government to strengthen the existing regulatory framework for coronary stents through:
The Cabinet Secretariat’s direction reaches the Health Ministry on 5 October, following Gopchade’s 29 September representation. This intervention places patient safety at the center of the regulatory agenda.
Also Read: India's Drug Pricing Architecture: Why the Rules Keep Expanding
AstraZeneca’s India arm partners with the National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, to build clinical research capabilities at 25 emerging sites.
The collaboration aims to extend pharmaceutical research beyond major metros. The partners will adopt the 25 clinical trial sites, assess their capabilities, and deliver targeted training in documentation and support processes related to ethics, safety and trial feasibility.
AstraZeneca India contributes clinical development expertise to design and deliver the program. The company supports participating sites through training, workshops, governance and site-readiness measures.
The Department of Pharmaceuticals provides strategic direction and endorsement under the Biopharma SHAKTI policy, which targets the establishment of 1,000 global-standard clinical trial sites across India.
Rao Akkinepally, Country President and Managing Director of AstraZeneca Pharma India, notes that clinical research remains central to bringing innovative medicines to patients.
The collaboration with NIPER Raebareli, backed by government support, strengthens India’s clinical research capabilities, expands trial participation and builds a sustainable, high-quality research ecosystem.
Manoj Joshi, Secretary, Department of Pharmaceuticals, adds that the partnership brings together government, academia and industry in a structured manner and advances key objectives of Biopharma SHAKTI.
Maharashtra’s government plans to launch an emergency air ambulance service on three major highways from early next year. Transport Minister Pratap Sarnaik announced coverage for Samruddhi Mahamarg (Mumbai-Nagpur highway), the Pune-Mumbai Expressway and the Mumbai-Goa highway.
The service aims to transport critically injured accident victims to hospitals during the golden hour. The first hour after an accident, when timely treatment significantly improves survival chances.
The state targets finalization and approval of a standard operating procedure by 15 November. A high-powered committee will grant approval by the end of November, after which the tendering process begins.
The proposed system focuses on air ambulance availability, safe transportation of injured victims to trauma care centers and coordination among emergency response agencies.
Aviation analyst Dhairyashil Vandekar observes that rapid urbanization, vehicle growth, and chronic traffic jams make reaching victims during the golden hour extremely challenging.
He emphasizes the need for seamless coordination among the National Highways Authority of India, Maharashtra State Road Development Corporation, health department, Directorate General of Civil Aviation, air traffic control authorities and hospitals.
These three developments illustrate a broader center-led pharma and healthcare push. Regulatory scrutiny of stents, strategic expansion of clinical trial infrastructure and parallel strengthening of emergency medical services together reinforce patient safety, research excellence and timely care across India.
.jpg)
